Abbott Laboratories has announced that the U.S. Food and Drug Administration (FDA) has granted approval for the Tendyne™ transcatheter mitral valve replacement (TMVR) system. This pioneering device offers a minimally invasive alternative for patients suffering from mitral valve disease due to severe mitral annular calcification $(MAC)$, particularly those who are not candidates for open-heart surgery. The Tendyne system, distinguished by its innovative design and availability in multiple sizes, can be delivered through a small chest incision and is fully repositionable during implantation. This approval further expands Abbott's portfolio of minimally invasive structural heart therapies in the U.S., reinforcing its leadership in mitral valve solutions.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。